NSE - Delayed Quote INR

Zydus Lifesciences Limited (ZYDUSLIFE.NS)

Compare
988.20 -17.50 (-1.74%)
At close: 3:30 PM GMT+5:30
Loading Chart for ZYDUSLIFE.NS
DELL
  • Previous Close 1,005.70
  • Open 1,012.00
  • Bid --
  • Ask --
  • Day's Range 983.95 - 1,013.05
  • 52 Week Range 567.75 - 1,324.30
  • Volume 1,334,037
  • Avg. Volume 2,394,873
  • Market Cap (intraday) 994.356B
  • Beta (5Y Monthly) 0.42
  • PE Ratio (TTM) 23.97
  • EPS (TTM) 41.23
  • Earnings Date Nov 5, 2024 - Nov 9, 2024
  • Forward Dividend & Yield 3.00 (0.30%)
  • Ex-Dividend Date Jul 26, 2024
  • 1y Target Est --

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

zyduslife.com

26,921

Full Time Employees

March 31

Fiscal Year Ends

Recent News: ZYDUSLIFE.NS

View More

Performance Overview: ZYDUSLIFE.NS

Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ZYDUSLIFE.NS
43.74%
S&P BSE SENSEX
11.05%

1-Year Return

ZYDUSLIFE.NS
71.13%
S&P BSE SENSEX
22.67%

3-Year Return

ZYDUSLIFE.NS
99.15%
S&P BSE SENSEX
31.67%

5-Year Return

ZYDUSLIFE.NS
330.30%
S&P BSE SENSEX
104.13%

Compare To: ZYDUSLIFE.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ZYDUSLIFE.NS

View More

Valuation Measures

Annual
As of 10/21/2024
  • Market Cap

    1.01T

  • Enterprise Value

    1.01T

  • Trailing P/E

    24.37

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.08

  • Price/Book (mrq)

    5.10

  • Enterprise Value/Revenue

    5.02

  • Enterprise Value/EBITDA

    16.12

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.34%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    206.15B

  • Net Income Avi to Common (ttm)

    41.69B

  • Diluted EPS (ttm)

    41.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.58B

  • Total Debt/Equity (mrq)

    3.72%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: ZYDUSLIFE.NS

View More

Company Insights: ZYDUSLIFE.NS

Research Reports: ZYDUSLIFE.NS

View More

People Also Watch